LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "oxybate" as a keyword



501 Clinical PK of XW10172 for Once Nightly Therapy in Patients with Narcolepsy or Sleep Disorders in Neurodegenerative Diseases

Sign Up to like & get
recommendations! Published in 2021 at "Sleep"

DOI: 10.1093/sleep/zsab072.500

Abstract: Patients with narcolepsy and patients with sleep disorders secondary to neurodegenerative diseases have been shown to respond to oxybate. To overcome the limitations of current oxybate therapies, we designed XW10172, a new chemical entity and… read more here.

Keywords: oxybate; sleep disorders; 501 clinical; xw10172 ... See more keywords

0411 Once-Nightly Sodium Oxybate Dose Titration and Tolerability: Interim Data From RESTORE

Sign Up to like & get
recommendations! Published in 2022 at "Sleep"

DOI: 10.1093/sleep/zsac079.408

Abstract: Extended-release, once-nightly sodium oxybate (ON-SXB; FT218) is under FDA review for the treatment of adults with narcolepsy. RESTORE, an ongoing, open-label extension/switch study (NCT04451668), evaluates long-term ON-SXB safety and tolerability. This interim analysis assessed dosing… read more here.

Keywords: titration; tolerability; oxybate; group ... See more keywords

0579 Long-Term Safety of Once-Nightly Oxybate for Narcolepsy: RESTORE Study Interim Analysis of Data

Sign Up to like & get
recommendations! Published in 2023 at "SLEEP"

DOI: 10.1093/sleep/zsad077.0579

Abstract: The pivotal phase 3 REST-ON trial (NCT02720744) evaluated the efficacy and safety of once-nightly sodium oxybate (ON-SXB; FT218), an investigational extended-release formulation for treatment of adults with narcolepsy. In REST-ON, ON-SXB met its 3 coprimary… read more here.

Keywords: safety; oxybate; sxb; restore study ... See more keywords

0584 Sodium Oxybate Treatment Patterns in Narcolepsy Patients: A Propensity Score–Matched Cohort Study Subanalysis

Sign Up to like & get
recommendations! Published in 2023 at "SLEEP"

DOI: 10.1093/sleep/zsad077.0584

Abstract: Sodium oxybate (SXB) is strongly recommended for treatment of narcolepsy. Patients treated with available immediate-release oxybates are required to awaken for a second dose 2.5–4 hours after the bedtime dose to cover a full night… read more here.

Keywords: second dose; oxybate; narcolepsy patients; discontinuation ... See more keywords

0985 Oxybate induced mania

Sign Up to like & get
recommendations! Published in 2023 at "SLEEP"

DOI: 10.1093/sleep/zsad077.0985

Abstract: Hypersomnia sleep disorders are characterized by overwhelming daytime sleepiness. Treatment options include sodium oxybate the sodium salt of γ-hydroxybutyric acid (GHB). Oxybate, an endogenous metabolite of GABA, acts through GABAB noradrenergic and dopaminergic neurons, as… read more here.

Keywords: hypersomnia; oxybate; sodium oxybate; mania ... See more keywords

0636 Assessing Usability of Once-Nightly Sodium Oxybate Extended-Release Oral Suspension for Narcolepsy

Sign Up to like & get
recommendations! Published in 2024 at "SLEEP"

DOI: 10.1093/sleep/zsae067.0636

Abstract: Sodium oxybate, available in once-nightly and twice-nightly formulations, is indicated for treatment of cataplexy or excessive daytime sleepiness in narcolepsy. Once-nightly sodium oxybate extended-release oral suspension (ON-SXB; LUMRYZ™) may alleviate potential dosing challenges associated with… read more here.

Keywords: sodium oxybate; use; release; oxybate extended ... See more keywords

0639 Long-term Safety and Timing of Adverse Events with Low-Sodium Oxybate in a Phase 3 Idiopathic Hypersomnia Study

Sign Up to like & get
recommendations! Published in 2024 at "SLEEP"

DOI: 10.1093/sleep/zsae067.0639

Abstract: Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration for the treatment of idiopathic hypersomnia in adults. To examine the long-term safety of LXB in this population, this post hoc analysis… read more here.

Keywords: idiopathic hypersomnia; common teaes; oxybate; safety ... See more keywords

0840 Oxybate Awareness, Usage, and Experience Among People with Narcolepsy: A MyNarcolepsyTeam Survey Analysis

Sign Up to like & get
recommendations! Published in 2025 at "SLEEP"

DOI: 10.1093/sleep/zsaf090.0840

Abstract: Narcolepsy is characterized by excessive daytime sleepiness (EDS) and can occur with or without cataplexy. Oxybates are FDA-approved to treat EDS or cataplexy in people with narcolepsy. Immediate-release twice-nightly sodium oxybate (TN-SXB) and calcium, magnesium,… read more here.

Keywords: awareness usage; people narcolepsy; treatment; survey ... See more keywords